The changing role of magnesium sulphate therapy

Current Opinion in Anaesthesiology

Volumn 12, Issue 3, 1999, Pages 283-287

  Breen, Terrance W ^a   Yang, Theresa ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MAGNESIUM SULFATE;

CEREBRAL PALSY; ECLAMPSIA; NEWBORN MORTALITY; PREECLAMPSIA; PREMATURITY; PRIORITY JOURNAL; RECURRENT DISEASE; SHORT SURVEY; TOCOLYSIS;

EID: 0032743921     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-199906000-00004     Document Type: Short Survey

References (35)

1. Mittendorf R, Covert R, Boman J, Khoshnood B, Lee KS, Siegler M. Is tocolytic magnesium sulphate associated with increased total paediatric mortality? Lancet 1997; 350: 1517-1518. This commentary reported the interim findings of the MAGnet (magnesium and neurological endpoints trial), which tried to ascertain whether antenatal magnesium decreases the frequency of cerebral palsy in preterm infants. They found 10 out of 11 neonatal deaths in the magnesium groups of patients, and because of this the study was suspended.
2. Idama TO, Lindow SW. Magnesium sulphate: a review of clinical pharmacology applied to obstetrics. Br J Obstet Gynaecol 1998; 105: 260-268. A good review of the obstetricians viewpoint about magnesium.
3. James MFM. Magnesium in obstetric anesthesia. Int J Obstet Anesth 1998; 7: 115-123. An obstetric anesthesiologist's view of magnesium.
4. Macones GA, Sehdev HM, Berlin M, Morgan MA, Berlin JA. Evidence for magnesium sulfate as a tocolytic agent. Obstet Gynecol Surv 1997; 52: 652-658.
5. Sciscione AC, Stamilio DM, Manley JS, Schlossman PA, Gorman RT, Colmorgen GHC. Tocolysis of preterm contractions does not improve preterm delivery rate or perinatal outcomes. Am J Perinatol 1998; 15: 177-181.
6. How HY, Cook CR, Cook VD, Miles DE, Spinnato JA. Preterm premature rupture of membranes: aggressive tocolysis versus expectant management. J Matern Fetal Med 1998; 7: 8-12.
7. Higby K, Xenakis EM-J, Pauerstein CJ. Do tocolytic agents stop preterm labor? A critical and comprehensive review of efficacy and safety. Am J Obstet Gynecol 1993; 168: 1247-1259.
8. Mittendorf R, Pryde P, Khoshnood B, Lee KS. If tocolytic magnesium sulphate is associated with excess total pediatric mortality, what is its impact? Obstet Gynecol 1998; 92: 308-311. This review article from the same authors who conducted the MAGnet trial reviewed the literature regarding neonatal deaths after antenatal exposure to magnesium. There is only one randomized trial of magnesium tocolysis that could support their findings but when deaths associated with congenital malformations were excluded there was no increased mortality in the magnesium group.
9. Cox SM, Sherman ML, Leveno KJ. Randomized investigation of magnesium sulfate for prevention of preterm birth. Am J Obstet Gynecol 1990; 163: 767-772.
10. Grether JK, Hoogstrate J, Selvin S, Nelson KB. Magnesium sulfate tocolysis and risk of neonatal death. Am J Obstet Gynecol 1998; 178: 1-6.
11. 4 treatment in newborns weighing 500-1500 g [abstract]. Am J Obstet Gynecol 1995; 172: 419.
12. Perlman J, Fernandez C, Gee J, Leveno K, Risser R. Magnesium sulfate (mg) administered to mothers with pregnancy induced hypertension (PIH) is associated with a reduction in periventricular-intraventricular hemorrhage [abstract]. Pediatr Res 1995; 38: 231.
13. Nelson KB, Grether JK. Can magnesium sulfate reduce the risk of cerebral palsy in very low birth weight infants? Pediatrics 1995; 95: 263-269.
14. Schendel DE, Berg CJ, Yeargin-Allsopp M, Boyle CA, Decoutle P. Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low birth weight children aged 3 to 5 years. JAMA 1996; 276: 1805-1810.
15. Fine-Smith RB, Roche K, Yellin PB, Walsh KK, Shen C, Zeglis M, et al. Effect of magnesium sulfate on the development of cystic periventricular leukomalacia in preterm infants. Am J Perinatol 1997; 14: 303-307.
16. Wilson-Costello D, Borawski E, Friedman H, Redline R, Fanaroff AA, Hack M. Perinatal correlates of cerebral palsy and other neurologic impairment among very low birth weight children. Pediatrics 1998; 102: 315-322.
17. Goldenberg RL, Rouse DJ. Preterm birth, cerebral palsy and magnesium. Nat Med 1997; 3: 146-147.
18. Nelson KB. Magnesium sulfate and risk of cerebral palsy in very low birth weight infants. JAMA 1996; 276: 1843-1844.
19. Leviton A, Paneth N, Susser M, Reuss ML, Allred EN, Kuban K, et al. Maternal receipt of magnesium sulfate does not seem to reduce the risk of neonatal white matter damage. Pediatrics (www.pediatrics.org). 1997; 99: e2
20. Paneth N, Jetton J, Pinto-Martin J, Susser M. Magnesium sulfate in labor and risk of neonatal brain lesions and cerebral palsy in low birth weight infants. Pediatrics (www.pediatrics.org). 1997; 99: e1
21. Spinillo A, Capuzzo E, Cavallini A, Stronati M, De Santolo A, Fazzi E. Preeclampsia, preterm delivery and infant cerebral palsy. Eur J Obstet Gynecol Reprod Biol 1998; 77: 151-155.
22. Perlman JM. Antenatal glucocorticoid, magnesium exposure, and the prevention of brain injury of prematurity. Semin Pediatr Neurol 1998; 5: 202-210.
23. The Eclampsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet 1995; 345: 1455-1463.
24. Lucas MJ, Leveno KJ, Cunningham FG. A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N Engl J Med 1995; 333: 201-205.
25. Khan KS, Chien PFW. Seizure prophylaxis in hypertensive pregnancies: a framework for making clinical decisions. Br J Obstet Gynaecol 1997; 104: 1173-1179.
26. Abi-Said D, Annegers JF, Combs-Cantrell D, Suki R, Frankowski RF, Willmore LJ. A case-control evaluation of treatment efficacy: the example of magnesium sulfate prophylaxis against eclampsia in patients with preeclampsia. J Clin Epidemiol 1997; 50: 419-423.
27. Coetzee EJ, Dommisse J, Anthony J. A randomised controlled trial of intravenous magnesium sulphate versus placebo in the management of women with severe pre-eclampsia. Br J Obstet Gynaecol 1998; 105: 300-303. This is the only trial comparing magnesium sulphate to placebo in women with severe pre-eclampsia, and it showed great benefit with the use of magnesium.
28. Witlin AG, Friedman SA, Sibai BM. The effect of magnesium sulfate therapy on the duration of labor in women with mild preeclampsia at term: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol 1997; 176: 623-627. This study demonstrated that the use of magnesium sulphate therapy in mild preeclampsia does not prolong the duration of labour but increases the dose of oxytocin used and the risk of postpartum haemorrhage.
29. Leveno KJ, Alexander JM, McIntire DD, Lucas MJ. Does magnesium sulfate given for prevention of eclampsia affect the outcome of labor? Am J Obstet Gynecol 1998; 178: 707-712.
30. Witlin AG, Sibai BM. Magnesium sulfate therapy in preeclampsia and eclampsia. Obstet Gynecol 1998; 92: 883-889.
31. Koinig H, Wallner T, Marhofer P, Andel H, Horauf K, Mayer N. Magnesium sulphate reduces intra- and postoperative analgesia requirements. Anesth Analg 1998; 87: 206-210.
32. Hodgson RE, Rout CC, Rocke DA, Louw NJ. Mivacurium for caesarean section in hypertensive parturients receiving magnesium sulphate therapy. Int J Obstet Anesth 1998; 7: 12-17.
33. Puri GD, Marudhachalam KS, Chari P, Suri RK. The effect of magnesium sulphate on hemodynamics and its efficacy in attenuating the response to endotracheal intubation in patients with coronary artery disease. Anesth Analg 1998; 87: 808-811.
34. Kyoung E, Bai SJ, Cho BJ, Shin Y-S. The infusion rate of mivacurium and its spontaneous neuromuscular recovery in magnesium-treated parturients. Anesth Analg 1998; 86: 523-526.
35. Kussman B, Shorten G, Uppington J, Comunale ME. Administration of magnesium sulphate before rocuronium: effects on speed of onset and duration of neuromuscular block. Br J Anaesth 1997; 79: 122-124.